A. V. Vardanyan

A. V. Vardanyan

Auto-generated profile, based on publicly available information

A. V. Vardanyan

Russian Medical Academy of Continuous Professional Education

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2024 in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
Verified
Journal Article
Open access
PDF file
АPА. S. Petrikov
А. S. Petrikov
ТVТ. V. Vavilova
Т. V. Vavilova
АVА. V. Vardanyan
А. V. Vardanyan
MZMikhail Zamyatin
Mikhail Zamyatin
IZIgor A. Zolotukhin
Igor A. Zolotukhin
ISIgor Suchkov
Igor Suchkov
On March 15, 2024, in Moscow, the Russian Phlebological Association and the National Association of Specialists in Thrombosis, Clinical Hemostasiology and Hemorheology organized a meeting of the Council of Experts during the Russian Forum on Thrombosis and Hemostasis on the acute issues of venous thromboembolism (VTE) primary prevention using low molecular weight heparins (LMWH) in surgical patients with different body weight. The participants reviewed the relevance and prevalence of this problem in surgical practice, discussed risk factors and the frequency of VTE development, including bleeding in the postoperative period, and the Caprini risk score for complications. The discussion also focused on standard and personalized LMWH doses for primary prophylaxis of VTE in the perioperative period in surgical patients, depending on body weight, and the role of laboratory tests, including assessment of LMWH anti-Xa activity for monitoring the efficacy and safety of VTE primary prevention in clinical practice.

1 February 2024 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
LFL. V. Fedina
L. V. Fedina
KMK. V. Mirzaev
K. V. Mirzaev
AVA. V. Vardanyan
A. V. Vardanyan
SGS. V. Glagolev
S. V. Glagolev
AKA. A. Kachanova
A. A. Kachanova
DSD A. Sychev
D A. Sychev
Aim. The aim of our study was to investigate the influence of polymorphic markers of CYP3A4*22 CYP3A4*22 (c.522-191C>T, rs35599367), CYP3A5*3 (c.219237A>G, rs776746), ABCB1 rs1045642 (c.3435T>C) and rs4148738 (c.2692-2236C>T) genes on the plasma concentration of apixaban, on changes in prothrombin time (PT), activated partial thromboplastin time (APTT), and bleeding development in patients taking apixaban.Material and methods. The study included 108 patients with non-valvular atrial fibrillation and deep vein thrombosis receiving apixaban in therapeutic doses. Genotyping was performed by real-time polymerase chain reaction. Apixaban concentrations were measured using an electrospray ionization mass spectrometer in positive ionization mode. Because the daily dose of apixaban was different (5, 10, and 20 mg daily), the residual equilibrium concentration (Cmin,ss) of apixaban was adjusted relative to the daily drug dose (Cmin,ss/D). PT and APTT were determined using an automatic coagulometer analyzer Destiny Max (Tcoag, Ireland). Statistical processing was performed in SPSS Statistics 20.0 program.Results. We found that patients with CT ABCB1 (rs4148738) C>T genotype had higher Cmin,ss /D value than patients with TT genotype (6.23 [4;13] vs 5.77 [4;17], p=0.018). No statistically significant associations were found between carriage of CYP3A4*22 (rs35599367) C>T, CYP3A5*3 A>G, ABCB1 (rs1045642) C>T gene polymorphisms and Cmin,ss /D value of apixaban. Also, there was no significant effect of carrying polymorphisms rs35599367, rs776746, rs4148738,rs4148642, and the above genes on the risks of hemorrhagic complications. However, the influence of ABCB1 (rs1045642) C>T polymorphism on the PT value was found (TT ABCB1 (rs1045642) C>T genotype carriers the CT value wassignificantly higher than in CT genotype (17.0 [40;112] vs. 14.9 [35;132]) p=0.044).Conclusion. It was found that the Cmin,ss /D value was higher in patients with CT ABCB1 (rs4148738) C>T genotype than in patients with TT genotype. At the same time, carriage of polymorphisms of CYP3A4*22 (rs35599367) C>T, CYP3A5*3 A>G, ABCB1 (rs1045642) C>T genes did not affect the pharmacokinetics of apixaban and the risk of bleeding. We also identified the effect of ABCB1 (rs1045642) C>T gene polymorphism on the PT value.

6 January 2023 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
LFL. V. Fedina
L. V. Fedina
ISIgor Sychev
Igor Sychev
TRT. D. Rastvorova
T. D. Rastvorova
ESE. V. Strigunkova
E. V. Strigunkova
AKA. A. Kachanova
A. A. Kachanova
DSDmitry Sychev
Dmitry Sychev
Aim. To investigate the effect of ABCB1 gene carriage and interdrug interactions on apixaban pharmacokinetics and clinical outcomes in patients with atrial fibrillation and deep vein thrombosis.Material and methods. Patients hospitalized at Yudin State Clinical Hospital participated in the study. A total of 92 patients (50 patients received apixaban and 42 – rivaroxaban) with non-valvular atrial fibrillation and deep vein thrombosis were included. Genotyping was performed by real-time polymerase chain reaction. Direct oral anticoagulants concentrations were measured using an electrospray ionization mass spectrometer in positive ionization mode.Results. In our study we found that in patients carrying the CT+TT ABCB1 (rs4148738) C>T genotype encoding the carrier protein (P-gp), the plasma concentration of rivaroxaban was statistically significantly higher p= 0.026. In addition, we found that patients taking apixaban together with a CYP3A4/P-gp inhibitor were 3.5 times more likely to have hemorrhagic complications than those without inhibitors p = 0.004.Conclusion. Our study revealed that the plasma concentration of rivaroxaban was higher in patients carrying the ABCB1 (rs4148738) C>T polymorphism T allele. And patients taking apixaban together with CYP3A4/P-gp inhibitor had higher risk of hemorrhagic complications in comparison with patients not taking such drugs. Further studies are needed on the influence of pharmacogenetics and pharmacokinetics on the safety and efficacy profile of apixaban and rivaroxaban, taking into account the trend of systemic approach to optimization of anticoagulant therapy of direct oral anticoagulants based on pharmacokinetic, pharmacogenetic biomarkers.

1 January 2023 in Endocrinology: News, Opinions, Training
Verified
Journal Article
Closed access
DDD.D. Dolidze
D.D. Dolidze
MBMoscow State Clinical Hospital Named After S.P. Botkin
Moscow State Clinical Hospital Named After S.P. Botkin
GCG.M. Chechenin
G.M. Chechenin
SCSerghei Covantsev
Serghei Covantsev
ZBZ.A. Bagatelya
Z.A. Bagatelya
DSD.V. Slepuhova
D.V. Slepuhova
Диагностическая ценность трепан-биопсии фолликулярных опухолей щитовидной железы

16 January 2024 in Atherothrombosis
Verified
Journal Article
Open access
PDF file
AIA. S. Igoshin
A. S. Igoshin
YKY. V. Karabaсh
Y. V. Karabaсh
AVA. V. Vardanyan
A. V. Vardanyan
EKE. E. Kislov
E. E. Kislov
ALA. V. Levin
A. V. Levin
Intimate sarcoma is a rare malignant tumor with a very poor prognosis. The incidence rate among all sarcomas is less than 1%. The primary localization of the tumor is most often the aorta and pulmonary artery. Other localizations account for about 10% of all observations. This tumor has an extremely nonspecific picture, is characterized by difficult diagnosis and poor prognosis. The main method of treatment is surgical – excision of the affected vessel and surrounding tissues with an interoperative histological examination, arterial reconstruction. About 140 cases of intimate sarcoma have been described in the literature. We present our own observation of intimate sarcoma. In the presented clinical case, the primary localization of the tumor was the common femoral artery. The patient was admitted with a clinical picture of a false femoral artery aneurysm, which was regarded as post-traumatic, without thrombosis or embolism of the distal bed and signs of limb ischemia. Repeated reconstructive surgical interventions were performed for a diagnosed false aneurysm. The intraoperative picture did not indicate any oncological process. After discharge, within six months there were two repeated requests for emergency indications in connection with erosive bleeding in the area of surgery. There were no signs of paraprosthetic infection. The oncological process was suspected with the appearance and growth of a voluminous formation of the inguinal region, which became the reason for performing a histological examination. The final diagnosis was made in the late stage of the disease, when radical surgical treatment was not feasible. The ongoing chemotherapeutic treatment did not have a significant effect, which led to an unfavorable outcome.

25 December 2025 in Ambulatornaya khirurgiya = Ambulatory Surgery (Russia)
Verified
Journal Article
Closed access
DMD. V. Matveev
D. V. Matveev
MKM. R. Kuznetsov
M. R. Kuznetsov
TST. V. Sorokina
T. V. Sorokina
AVA. V. Vardanyan
A. V. Vardanyan
DDD. D. Dolidze
D. D. Dolidze
AKA. A. Karpov
A. A. Karpov
Introduction. Telangiectasias and reticular veins (C1 by CEAP) cause aesthetic discomfort; standard sclerotherapy has side effects like pigmentation. Ozone-oxygen mixture offers an alternative via oxidative endothelial damage and tissue oxygenation. Aim. To evaluate the efficacy and safety of intravascular sclerotherapy using an ozone-oxygen gas mixture for telangiectasias and reticular varicose veins of the lower extremities. Materials and methods. The study included 30 patients (25 women and 5 men) with telangiectasias and reticular varicose veins (class C1 by CEAP). All patients underwent a course of sclerotherapy consisting of intravascular injections of an ozone-oxygen mixture into the affected superficial veins using a microneedle (ozone concentration was 70%). Procedures were performed on an outpatient basis once per week; the mean number of sessions per patient was 4.2 ± 1.1. Treatment efficacy was evaluated at 30 days after completion of therapy based on the degree of vascular network disappearance and patient satisfaction. Results. 93% of patients (28/30) achieved complete or significant (>75%) obliteration of telangiectasias and reticular veins after the treatment course. No serious complications were observed. Side effects were limited to transient erythema, mild edema and moderate pain at injection sites, which resolved spontaneously. No cases of skin hyperpigmentation, necrosis or scarring were noted. The cosmetic outcome was high: 97% of patients were satisfied with the results. Conclusion. Ozone-oxygen injection sclerotherapy is an effective and safe method for sclerobliteration of telangiectasias and reticular varicose veins, providing excellent cosmetic results with minimal invasiveness. The technique does not induce typical adverse reactions such as hyperpigmentation or scarring, and it expands options for minimally invasive treatment of early-stage varicose vein disease, thereby improving patients’ quality of life.